Botulinum toxin as a therapy for cerebral palsy

被引:0
|
作者
Raj, S. A. [1 ]
Adithya, S. [1 ]
Shanker, A. [1 ]
Ahmad, F. [1 ]
机构
[1] Vellore Inst Technol, Sch Bio Sci & Technol, Dept Biotechnol, Vellore 632014, India
来源
RESEARCH JOURNAL OF BIOTECHNOLOGY | 2024年 / 19卷 / 04期
关键词
Botox; physiotherapy; motor functions; gait; muscle spasticity; DOUBLE-BLIND; CONTROLLED-TRIAL; UPPER-LIMB; CHILDREN; MOTOR; INJECTION; ADULTS; INTERVENTION; RELIABILITY; MECHANISMS;
D O I
10.25303/1904rjbt1350141
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cerebral palsy (CP) is a neuromuscular condition caused by deficits in the developmental trajectory of the brain or due to physical injury to the developing brain. It affects many school -going and newly born children and is indicated by exaggerated movements and reflexes and unusual movements of the limbs, digits and posture. The present review article discusses the therapeutic potential of botulinum toxin (BoNT) for the treatment of CP. BoNT is a well-known commercially available neurotoxin which blocks the release of neurotransmitters (e.g. acetylcholine), thereby decreasing the undesirable muscle movement of the voluntary muscles in the case of CP. The review also discusses the effectiveness of the therapy, rehabilitation of the patients after treatment and various scales used to measure the movement before and after therapy.
引用
收藏
页码:135 / 141
页数:152
相关论文
共 50 条
  • [41] Botulinum toxin type A in the treatment plan for cerebral palsy
    Strobl, W
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2001, 113 : 30 - 35
  • [42] The effect of botulinum toxin in the treatment of spasticity in cerebral palsy
    Watanabe, Y
    Bakheit, AMO
    McLellan, DL
    [J]. 8TH WORLD CONGRESS OF THE INTERNATIONAL REHABILITATION MEDICINE ASSOCIATION (IRMA VIII), PTS 1-2, 1997, : 873 - 876
  • [43] Use of botulinum toxin type A in children with cerebral palsy
    Nolan, KW
    Cole, LL
    Tak, GSL
    [J]. PHYSICAL THERAPY, 2006, 86 (04): : 573 - 584
  • [44] Comment on: “Botulinum Toxin in the Management of Children with Cerebral Palsy”
    Katherine Langdon
    Lisa Copeland
    Priya Edwards
    Kate Rodwell
    Kim McLennan
    Theresa Carroll
    Sasaka Bandaranayake
    Adam Scheinberg
    Mary-Clare Waugh
    Heather Burnett
    Neil Wimalasundera
    Sabine Hennel
    Eewei Lim
    Steve O’Flaherty
    [J]. Pediatric Drugs, 2019, 21 : 493 - 495
  • [45] Use of botulinum toxin in pediatric spasticity (Cerebral Palsy
    Berweck, S
    Heinen, F
    [J]. MOVEMENT DISORDERS, 2004, 19 : S162 - S167
  • [46] Treatment of sialorrhea with botulinum toxin A in patients with cerebral palsy
    Tilton, AH
    Suskind, D
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (03) : S118 - S118
  • [47] Use of botulinum toxin in 55 children with cerebral palsy
    Mohammadi, M
    [J]. CEREBRAL PALSY AT THE TURN OF THE MILLENNIUM, 2001, : 105 - 112
  • [48] Position paper on the use of botulinum toxin in cerebral palsy
    Carr, LJ
    Cosgrove, AP
    Gringras, P
    Neville, BGR
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 1998, 79 (03) : 271 - 273
  • [49] Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy"
    Langdon, Katherine
    Copeland, Lisa
    Edwards, Priya
    Rodwell, Kate
    McLennan, Kim
    Carroll, Theresa
    Bandaranayake, Sasaka
    Scheinberg, Adam
    Waugh, Mary-Clare
    Burnett, Heather
    Wimalasundera, Neil
    Hennel, Sabine
    Lim, Eewei
    O'Flaherty, Steve
    [J]. PEDIATRIC DRUGS, 2019, 21 (06) : 493 - 495
  • [50] Botulinum toxin for cerebral palsy; where are we now?
    Morton, RE
    Hankinson, J
    Nicholson, J
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (12) : 1133 - 1137